Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 4Carcinoma, Ovarian Epithelial 4Rectal Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Melanoma 2Head and Neck Neoplasms 2Gliosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Osteosarcoma 1Oligodendroglioma 1

Interventions

Doxorubicin 15Exercise 9Cyclophosphamide 9Dexrazoxane 8Razoxane 6Carvedilol 6Vincristine 4Trastuzumab 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Echocardiography 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Leucovorin 2Ivabradine 2High-Intensity Interval Training 2Epirubicin 2Electrocardiography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cardiotoxicity × Mass Spectrometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡